Sandoz to Launch Hyrimoz High-Concentration Formulation Biosimilar in the US
Shots:
- The company will launch citrate-free high-concentration formulation (HCF) of biosimilar Hyrimoz (adalimumab-adaz) injection in the US
- Hyrimoz HCF (100mg/mL) is approved for indications that are no longer covered exclusively for the reference medicine incl. RA, PsA, CD, JIA, AS, UC, PsO & hidradenitis suppurativa. It uses the same auto-injector as Hyrimoz 50 mg/mL, the Sensoready pen
- Hyrimoz was approved in the US in 2018 at a concentration of 50mg/mL. The HCF offers a 50% reduction over the original concentration and can decrease the number of inj. required for people who need at least 80mg/0.8 mL dosing
Ref: sandoz | Image: sandoz
Related News:- Sandoz’s Hyrimoz (biosimilar, adalimumab) Receives EC’s Marketing Authorization for Multiple Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
